

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Narhi, et al.

Serial No.: 09/284,100

Group Art Unit No.: 1646

Filed: April 7, 1999

Examiner: S. Prasad

For: KERATINOCYTE GROWTH FACTOR-2 PRODUCTS

Docket No.: A-423C

#13
Om21
8-17-01RECEIVED
MAR 12 1999
COMM-FIELD

INFORMATION DISCLOSURE STATEMENT
BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97(c))

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

Publication No. JP 6345666 is not in English. Applicants have attached an English abstract in support of this publication. Publication No. WO 97/20929A1 is not in English. Applicants have attached an English abstract in support of this publication.

Pursuant to Rule 1.98(a)(i), Applicants bring to the attention of the Examiner, and **include a copy of as an attachment to this Information Disclosure Statement**, the following copending United States Patent Application:

09/284,101 filed April 7, 1999

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

- A ☐ a statement as specified in 37 CFR 1.97(e):

STATEMENT

I, the person(s) signing below state:

- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). **An original and one copy are enclosed.**

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Thomas D. Zindrick
Attorney/Agent for Applicant(s)
Registration No.: 32,185
Phone: (805) 447-8101
Date: June 8, 2001

Please send all future correspondence to:

US Patent Operations/TDZ
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799